Mike Hollan

The PGDx elio plasma focus Dx offers laboratories testing options for situations where samples are hard to obtain.

The app provides users with lifestyle tips and plans based on the lifestyles of people living in regions with the highest lifespans.

Integrated Delivery Networks have impacted everything from drug launches to sales approaches.

The report also details steps that employers are taking to manage the cost of healthcare plans for employees.

The company announced that it will conduct research based on guidance from the agency.

Ouva’s AI-powered technology will be added to AvaSure’s digital platform.

The company plans to develop these treatments using it’s AI-powered platform.

MGI Tech Co. issued a statement detailing the use of its technology in improving the rates of genomic sequencing in South Africa.

An unexpected consequence of the COVID 19 pandemic has been a loss in trust of vaccines. Over the past three flu seasons, there has been a drop in vaccination rates that is alarming experts. Dr. Gregg Sylvester, chief health officer at CSL Seqirus, spoke with Pharmaceutical Executive about the causes of the decline and how important it is to get the rates back to normal.

The partnership will allow both group to expand their operations and provide more solutions to underserved communities.

The lead transformation evangelist at Celonis discusses how digital twins are becoming more prominent in the pharma industry.

Biocon Biologic’s chief commercial officer of advanced markets discusses the current market and potential trends for biosimilars.

The PBM defined its core values and what role it believes PBMS should play in the industry.

The deals leader at EY Global Life Sciences discusses how the first half of 2024 fared compared to 2023’s strong ending.

The company received the money through a government project agreement.

The AI-powered feature will provide detailed nutritional information based on photos of food taken by users.

Dx&Vx identified multiple potential drug candidates using AI-based technology.

The two companies will continue to collaborate on the use of machine learning in improving precision medicine development.

This is the latest approval for Phathom Pharmaceutical’s GI treatment.

The tech company’s data platform will be implemented into the genomic research department’s workflow.

The network includes organizations that represent over 45,000 agents and brokers.

Ripston discusses the Biospecimen Management Consortium and how its working to develop best practices for driving sample excellence.

The two companies will use Astrana’s technology offerings to improve access.

EVERSANA’s senior vice president of innovation discusses how the technology has been implemented in various areas of the pharmaceutical industry.

The global president of endomechanical and energy for Johnson & Johnson MedTech discusses the need for multidisciplinary care when treating obesity.

Empara’s virtual assistant is the latest attempt to use AI to simplify the user experience in the healthcare industry.

The AscellaHealth CEO discusses how new technologies are increasing the options in patient care.

The CEO of Revelation Pharma discusses how compounding pharmacies may help solve the ongoing issue with drug shortages.

Dr. Varshney discusses how AI is being used to sort data and discover new molecules and indications for existing drugs.

The compounding pharmacy acquired Taylors Pharmacy and Key Compounding Pharmacy.